Krintafel™ (tafenoquine) – New drug approval
July 20,2018 - GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) announced the FDA approval of Krintafel (tafenoquine), for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
Top